Xiankai Liu

Title: Xiankai Liu: Innovator in Immunogenic Protein Development

Introduction

Xiankai Liu is a prominent inventor based in Beijing, China. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of immunogenic proteins. His work focuses on creating innovative solutions to combat infections through advanced protein compositions.

Latest Patents

Xiankai Liu holds a patent for an immunogenic protein and its composition and application. This invention discloses a protein that comprises 39 amino acids from the N-terminal α-helix part of the Ata protein transport functional domain. The amino acid sequence of these 39 amino acids is represented by the 127-165 amino acid residues of SEQ ID NO:2. The invention involves fusing these amino acids with CTB and expressing them in BL21. The protein is purified using a nickel column and is utilized for intraperitoneal immunization in mice at a dosage of 2.5 μg/mouse. The immunogenicity and immunoprotection of this protein were verified through animal experiments, demonstrating its effectiveness in anti-infection applications.

Career Highlights

Xiankai Liu is associated with Chengdu Olymvax Biopharmaceuticals Inc., where he continues to advance his research in immunogenic proteins. His innovative approach and dedication to biopharmaceutical development have positioned him as a key figure in the industry.

Collaborations

Xiankai Liu has collaborated with notable colleagues, including Hengliang Wang and Li Zhu. Their combined expertise contributes to the success of their research initiatives and the advancement of immunogenic protein applications.

Conclusion

Xiankai Liu's work in the field of immunogenic proteins showcases his commitment to innovation and research in biopharmaceuticals. His contributions are paving the way for new solutions in infection prevention and treatment.